Endocrine Abstracts

Antithyroid drugs represent mainly the first choice therapy in hyperthyroid Graves’ disease. Their therapeutical ineffectiveness can lead to the onset or the severity of ophthalmopathy associated with Graves’ disease. Type 2 5’-deiodinase enzyme (DIO2) plays a crucial role besides type 1 5’-deiodinase enzyme in the development of Graves’ hyperthyroidism. Anti-thyroid drugs inhibit the activity of both type 5’-deiodinases blocking the synthesis of ...

Introduction: Paragangliomas are rare neuroendocrine tumors that arise from the extraadrenal paraganglia. Sympathetic paragangliomas usually secrete catecholamines and are located in the sympathetic paravertebral ganglia of thorax, abdomen and pelvis.Case report: We present a 66 year old patient with an incidentally found retroperitoneal mass on spine MRI. An open biopsy was performed (9/15) with the histological finding of benign paraganglioma (accordin...

BackgroundOnly limited data are available regarding adverse effects of gender affirming hormonal treatment (HT) mainly due to the lack of population-based studies with adequate controls, thus making spontaneous reporting systems a valuable tool to detect potential side reactions.ObjectiveIn this nationwide retrospective study, we aimed to analyse adverse drug reactions (ADRs) in relation to gender affirming H...

Myasthenia gravis (MG) and Graves’ ophthalmopathy (GO) share many clinical characteristics but may also co-exist. Both are autoimmune disorders mediated by organ specific pathogenic autoantibodies to membrane surface receptors. Differential diagnosis and/or co-existence provides a potential management challenge, and there is a paucity of demographic information regarding precise prevalence rates and concurrence of disease.Method: Re...

Background: Thyroid eye disease (TED) affects 25% of patients with Graves’ disease (GD). GD affects nearly 1% of pregnancies. However, data on TED incidence, course, management and outcome in pregnancy are limited.Aims: To describe the prevalence, course and outcomes of TED in pregnant females.Methods: A retrospective analysis of electronic health records was conducted in a sp...

Introduction: Patients with type 1 diabetes mellitus (DM1) present a high prevalence of autoimmune associated diseases. Recently, we described a prevalence of latent pernicious anemia (LPA) of 12.4% in DM1.Objectives: A 5-year follow-up study of a cohort of DM1 patients in order to evaluate the evolution of biochemical markers of LPA, defined as a serum pepsinogen I (PI) concentration below normal limits.Material and methods: One h...

Introduction: Tumor-induced osteomalacia is a rare paraneoplastic syndrome characterized by the presence of phosphaturic hormone-secreting mesenchymal tumors - fibroblast growth factor 23 (FGF-23), which causes hypophosphatemia and osteomalacia. These tumors are small, frequently infiltrate the surrounding tissues and are located in the connective or bone tissue. Usually, these tumors are benign, but malignant tumors have also been reported.Case report: ...

Background and objective: Multiple Endocrine Neoplasia type 1 (MEN 1) is an autosomal dominant disease characterized by a broad clinical spectrum. Previous multi-center studies, that analyzed large groups of patients with MEN 1 have been reported before but long term follow up data of these patients focusing exclusively on primary hyperparathyroidism (PHPT) are scarce.Patients and Methods: In this retrospective cohort study we include all patients with P...

Background: Primary hyperaldosteronism (PA) is a prevalent, but underdiagnosed syndrome. Diagnosis and treatment have been relatively constant since the development of the latest Endocrine Society guidelines in 2016.Study objective: Baseline characteristics, treatment and follow-up of subjects with PA referred for adrenal venous sampling (AVS) in a tertiary hospital since 2009 are presented.Results: Thirty five subjects (M/F: 17/18...

Objective: Vitamin D has potential immunomodulatory effects. We studied whether vitamin D3 supplementation affects the course of Graves’ disease (GD).Methods: In a double-blind, placebo-controlled design, we randomized patients with a first time diagnosis of GD hyperthyroidism to daily supplementation with vitamin D3 70 mg (2800 IU) or placebo, as add-on to standard treatment with anti-thyroid drugs (ATD). The intervention was continued 12 months af...